Literature DB >> 28440416

FUCA1 is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status.

Nobuo Tsuchida1, Masa-Aki Ikeda1, Υoshizumu Ιshino2, Michele Grieco3, Giancarlo Vecchio4.   

Abstract

Fucose residues of cell surface glycans, which play important roles in growth, invasion and metastasis, are added by fucosyltransferases (FUTs) and removed by α-L-fucosidases (FUCAs). By the differential display method, we isolated a 3' non-coding region of α-L-fucosidase-1 (FUCA1) (a gene coding for the lysosomal fucosidase-1 enzyme) as a wild-type p53-inducible gene: 18S and 20S FUCA1 mRNA species were induced in Saos-2 cells transfected with a temperature-sensitive p53 mutant at the permissive temperature. By microarray analyses of thyroid cancer biopsy samples, FUCA1 RNA expression levels were found to be lower in anaplastic thyroid cancer samples (ATCs), while they were higher in papillary thyroid cancer samples (PTCs) and in normal thyroid tissues. Since most ATCs were reported to carry the mutated form of p53, while PTCs carry mostly the wild-type form of p53, it is likely that FUCA1 expression levels are regulated, at least in part, by the p53 status in thyroid cancers. In order to better understand the role played by FUCA genes in thyroid tumorigenesis, we examined the clonogenic potential in vitro of thyroid cell lines transfected with either FUCA1 or FUCA2 (the latter gene coding for a secreted, non-lysosomal enzyme). We found that α-L-fucosidases did not suppress grossly cell growth. Contrary to what we observed with the expression of FUCA1, the FUT8 expression levels were found high in ATCs but lower in PTCs and normal thyroid tissues. Taken together, these results suggest the possibility that the higher fucose levels on cell surface glycans of aggressive ATCs, compared to those of less aggressive PTCs, may be at least in part responsible for the more aggressive and metastatic phenotype of ATCs compared to PTCs, as the expression levels of FUCA1 and FUT8 were inversely related in these two types of cancers.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28440416     DOI: 10.3892/ijo.2017.3968

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Plasma alpha-L-fucosidase activity in chronic inflammation and autoimmune disorders in a pediatric cohort of hospitalized patients.

Authors:  Ildikó Endreffy; Geir Bjørklund; László Szerafin; Salvatore Chirumbolo; Mauricio A Urbina; Emőke Endreffy
Journal:  Immunol Res       Date:  2017-10       Impact factor: 2.829

2.  Downregulation of α-l-fucosidase 1 suppresses glioma progression by enhancing autophagy and inhibiting macrophage infiltration.

Authors:  Lixia Xu; Zhenwei Li; Sirong Song; Qian Chen; Lidong Mo; Chen Wang; Weijia Fan; Yan Yan; Xiaoguang Tong; Hua Yan
Journal:  Cancer Sci       Date:  2020-05-16       Impact factor: 6.716

3.  Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection.

Authors:  Yuxiang Deng; Yujie Zhao; Wenhua Fan; Jianhong Peng; Xiao Luo; Yiwen Mo; Binyi Xiao; Lin Zhang; Zhizhong Pan
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

Review 4.  Dual role of fucosidase in cancers and its clinical potential.

Authors:  Jinxing Fu; Qing Guo; Yuan Feng; Peng Cheng; Anhua Wu
Journal:  J Cancer       Date:  2022-08-15       Impact factor: 4.478

5.  Reduced expression of α-L-Fucosidase-1 (FUCA-1) predicts recurrence and shorter cancer specific survival in luminal B LN+ breast cancer patients.

Authors:  Serena Bonin; Alessia Parascandolo; Cinzia Aversa; Renzo Barbazza; Nobuo Tsuchida; Maria Domenica Castellone; Giorgio Stanta; Giancarlo Vecchio
Journal:  Oncotarget       Date:  2018-02-07

Review 6.  Glycosylation in the Thyroid Gland: Vital Aspects of Glycoprotein Function in Thyrocyte Physiology and Thyroid Disorders.

Authors:  Marta Ząbczyńska; Kamila Kozłowska; Ewa Pocheć
Journal:  Int J Mol Sci       Date:  2018-09-17       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.